Thyroid Concerns
Potential risk of thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), based on findings in rodent studies. Carries an FDA black box warning.
Prevalence
Observed in animal studies; human incidence not established (FDA black box warning)
Severity
Rare
Category
Serious / Rare
Why It Happens
In animal studies (rats and mice), GLP-1 receptor agonists caused dose-dependent thyroid C-cell tumors, including medullary thyroid carcinoma. This is thought to be related to GLP-1 receptor activation on thyroid C-cells, which stimulates calcitonin release. However, human thyroid C-cells have significantly fewer GLP-1 receptors than rodents, and decades of human data have not shown a clear increased risk in humans. The black box warning remains as a precaution.
Timeline
In rodent studies, tumors developed with chronic long-term exposure. There is no established timeline for human risk. The FDA warning applies for the entire duration of treatment.
Management Tips
Disclose any personal or family history of medullary thyroid carcinoma (MTC) to your doctor
Disclose any personal or family history of Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
Be aware of thyroid cancer symptoms: a lump or swelling in the neck
Report persistent hoarseness, difficulty swallowing, or shortness of breath
Follow your doctor's monitoring recommendations
When to See Your Doctor
Report any lump or swelling in the neck, persistent hoarseness or voice changes, difficulty swallowing, or shortness of breath. These may be signs of thyroid issues unrelated to medication, but they should always be evaluated.
Medications That May Cause Thyroid Concerns
SeraVia GLP-1 Support
Selenium and iodine support for overall thyroid health during GLP-1 therapy — always discuss thyroid concerns with your doctor
Learn More →Thyroid Concerns FAQs
Does Ozempic cause thyroid cancer?
GLP-1 medications carry an FDA black box warning about thyroid C-cell tumors based on rodent studies. However, human thyroid cells have far fewer GLP-1 receptors than rodent cells, and large human studies have not confirmed an increased thyroid cancer risk. The warning is precautionary. Patients with a history of medullary thyroid carcinoma or MEN 2 should not use GLP-1 medications.
Who should NOT take GLP-1 medication due to thyroid risk?
GLP-1 receptor agonists are contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). If you have any thyroid cancer history, discuss it thoroughly with your doctor.
Should I get thyroid screening while on GLP-1 medication?
Routine thyroid cancer screening specifically for GLP-1 use is not currently recommended by major medical organizations. However, you should report any neck lumps, voice changes, or swallowing difficulties to your doctor. Standard thyroid function tests (TSH) during regular checkups are reasonable.
Talk to a provider about managing thyroid concerns
If thyroid concerns is affecting your quality of life, a qualified provider can adjust your dose or recommend management strategies.
Find a Provider →Get weekly GLP-1 side effect management tips
Evidence-based strategies, new research, and product recommendations — delivered to your inbox.
No spam. Unsubscribe anytime.
Explore all GLP-1 side effects
Understand every potential side effect, how to manage them, and when to seek medical attention. Knowledge is your best tool.